Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

This study has been completed.

Study NCT00039481 Information provided by National Cancer Institute (NCI)

First Received: June 6, 2002 Last Updated: December 28, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	October 2005 (Final data collection date for primary outcome measure)

Publications:

Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC; Children's Oncology Group Study. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Apr 20;25(12):1512-8.

Rheingold S, Krailo M, Blaney S, et al.: A Phase I trial of G3139 (Bcl-2 Antisense) combined with cytotoxic chemotherapy in relapsed pediatric solid tumors - a Children's Oncology Group study. [Abstract] J Clin Oncol 23 (Suppl 16): A-3102, 217s, 2005.